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The purpose of this exploratory research is to provide data on synaptopathy in the behavioral variant 
of frontotemporal dementia (bvFTD). Twelve patients with probable bvFTD were compared to 12 
control participants and 12 patients with Alzheimer’s disease (AD). Loss of synaptic projections was 
assessed with  [18F]UCBH-PET. Total distribution volume was obtained with Logan method using 
carotid artery derived input function. Neuroimages were analyzed with SPM12. Verbal fluency, 
episodic memory and awareness of cognitive impairment were equally impaired in patients groups. 
Compared to controls,  [18F]UCBH uptake tended to decrease in the right anterior parahippocampal 
gyrus of bvFTD patients. Loss of synaptic projections was observed in the right hippocampus of AD 
participants, but there was no significant difference in  [18F]UCBH brain uptake between patients 
groups. Anosognosia for clinical disorder was correlated with synaptic density in the caudate nucleus 
and the anteromedial prefrontal cortex. This study suggests that synaptopathy in bvFTD targets the 
temporal social brain and self-referential processes.
Frontotemporal lobar degeneration (FTLD) is a heterogeneous group of diseases that affect anterior brain regions 
associated with personality, behavior, executive functions and language deficits. The pathophysiology in most 
cases of FTLD includes an abnormal intracellular accumulation of disease specific proteins, such as tau or 
transactive response-DNA binding protein-43 (TDP-43). FTLD is associated with ventromedial and dorsolat-
eral frontal and anterior temporal gray matter loss and glucose  hypometabolism1. Even patients with very mild 
dementia may show atrophy in anterior cortical (comprising paralimbic frontal) and subcortical (striatal and 
thalamic)  regions2. There is also a significant white matter degradation in association and commissural tracts 
(such as the uncinate and longitudinal fasciculi and the corpus callosum) in  FTLD3. Using fMRI, the intrinsic 
connectivity network disrupted in the behavioural variant of frontotemporal dementia (bvFTD, a subgroup 
of FTLD, was shown to involve the anterior cingulate cortex, frontal insula and striatum, related to emotional 
salience processing  capacities4.
Accumulating evidence indicates that neuronal death in neurodegenerative diseases is preceded by disruption 
of synapses. Abnormal brain connectivity (connectopathy) or synaptopathy have been described in  FTLD5–7. 
Extensive synaptic loss and reduction in the number of spines have been documented post-mortem in the 
diseased  cortex8–10. More precisely, a significant decrease in synaptic density measured with synaptophysin was 
reported in the superficial layers of the prefrontal cortex of FTLD cases compared with normal controls in  some10, 
but not all  studies11. In Pick’s disease, synaptophysin immunoreactivity was also reduced in the outer molecular 
layer of the hippocampal dentate  gyrus12.
The aim of this study was to measure brain synaptic density in vivo using synaptic vesicle protein 2A-PET in 
patients with  bvFTD13–15. SV2A-PET has been recently used to assess synaptopathy in different neuropsychiatric 
 conditions13–15, and frontotemporal involvement was recently reported in a patient with C9orf72  mutation16. 
We anticipated loss of synaptic density in the frontal and temporal poles and we searched for precise regional 
loss of synaptic projections. We have a particular interest in anosognosia as an early marker of neurocognitive 
 disorders17, and we anticipated that decreased awareness for clinical symptoms, a frequent behavioral disorder 
observed in about 85% of bvFTD  patients18 would be related to frontal and/or temporal  synaptopathy19.
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Results
Neuropsychological assessments. All values for cognitive performance and anosognosia measures in 
bvFTD and AD patients were significantly different from those in controls (Table 1). There was no significant 
difference between AD and bvFTD groups.
SV2A comparisons. The brain distribution of  [18F]UCB-H is illustrated in Fig. 1. For the bvFTD sample, 
there was a trend  (PFWE corr = 0.077) for a decrease in the distribution volume of  [18F]UCB-H in a right parahip-
pocampal region (BA36), close to the amygdala (Fig. 2 and Table 2). Loss of Vt in the cluster, calculated as (mean 
patients − mean controls)/mean controls × 100, was 41% compared to the control value.
We ran a seed to voxel connectivity analysis using CONN toolbox implemented in  MATLAB20 and resting-
state fMRI from 27 healthy elderly volunteers from an independent sample (Supplemental Table 1), and the 
right parahippocampal seed, corresponding to the peak of decreased synaptic projections in the bvFTD group 
(Supplemental Fig. 1). It was largely connected to the bilateral temporal poles and the right orbitofrontal cortex 
(p < 0.05 False Discovery Rate-corrected at the voxel level).
For the AD sample, there was a trend  (PFWE corr = 0.078) for a reduced synaptic density in the right hip-
pocampus. Loss of Vt in the cluster was 33% compared to controls.
When patient groups were directly compared, there was a non-significant (but p < 0.001, uncorrected) 
decrease in Vt in the left precuneus (BA7) in AD compared to bvFTD.
Table 1.  Demographic and clinical data. W women, M men, MMSE mini mental state exam, CDR clinical 
dementia rating, AQ-D Anosognosia Questionnaire for Dementia, MARS memory awareness rating scale.
bvFTD AD Controls
Age (years) 73.5 ± 7.6 74.1 ± 8.6 71.4 ± 5.2
Sex (W/M) 4/8 5/7 5/7
Education (years) 11.5 ± 4.1 11.8 ± 3.7 13.1 ± 3.6
Disease duration (years) 5.2 ± 3.4 6.2 ± 3.9 N/A
MMSE 25.4 ± 3.1 25.1 ± 2.6 29.1 ± 1.1
CDR (0.5/1/2) 1/8/3 2/10/0 N/A
DMS48 (% correct) 86.9 ± 14.9 85.9 ± 8.8 98.2 ± 2.1
Fluency (letter p) 13.3 ± 4.4 17.9 ± 7.7 20.4 ± 5.2
AQ-D difference 15.1 ± 13.3 5.4 ± 14.2 1.9 ± 5.9
MARS discrepancy score 0.4 ± 0.4 0.1 ± 0.4 0.0 ± 0.1
Figure 1.  Coronal PET images of the brain distribution volume (Vt) of  [18F]UCBH in a bvFTD patient and a 
control participant. [color required].
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SV2A correlations. For the bvFTD group, there was a significant negative correlation between anosog-
nosia measured with the AQ-D and Vt in the right caudate head (r = − 0.89, pFWE = 0.023, Table 2 and Fig. 3) 
and a trend with Vt in the right frontal pole (r = − 0.87, pFWE = 0.058). The latter correlation was significant 
(pFWE = 0.009) when compared to controls or to AD participants.
We ran seed to voxel connectivity analysis using CONN toolbox and fMRI from our 27 healthy elderly 
volunteers, and caudate nucleus was connected with a large cluster centered on the anterior cingulate cortex, 
comprising the frontal pole (p < 0.05 FDR-corrected at the voxel level, Supplemental Fig. 2).
Figure 2.  Plots of  [18F]UCBH distribution volumes (Vt) measured in the right parahippocampal cortex (see 
cross on the figure) of control participants and patients with bvFTD and AD.
Table 2.  Neuroimaging results. AQ-D Anosognosia Questionnaire for Dementia, AMPFC anteromedial 
prefrontal cortex, R right, L left, m medial.
x y z Voxels Z
Comparison bvFTD < CTRL
R. Parahippocampal gyrus 18 − 2 − 38 85 4.03
Comparison AD < CTRL
R. Hippocampus 14 − 8 − 18 80 4.06
Correlation AQ-D difference in bvFTD
R. Caudate 12 16 6 574 4.52
m. AMPFC 4 58 8 492 4.26
Correlation AQ-D difference in AD
R. Posterior hippocampus 12 − 42 8 431 4.10
Atrophy in bvFTD < CTRL
m. AMPFC − 8 68 − 2 300 3.84
Atrophy in AD < CTRL
L. Parietal − 62 − 62 30 1146 5.10
R. Posterior hippocampus 36 − 32 − 10 787 5.06
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For the AD group, there was a trend for a negative correlation between anosognosia measured with the AQ-D 
and the left posterior hippocampus (pFWE = 0.088) when compared to controls.
VBM analyses. For the bvFTD group compared to controls, there was a trend for atrophy in the medial 
prefrontal cortex (p < 0.001 uncorrected at the voxel level and pFWE = 0.032 at the cluster level, Table 2).
For the AD group compared to control, there was an atrophy of the right posterior hippocampus 
(pFWE = 0.010) and the bilateral posterior associative cortices (pFWE = 0.036, Table 2).
The direct comparison between patient groups did not provide any significant difference. There was no sig-
nificant correlation with the clinical data.
We computed a correlational analysis between frontal atrophy (GM density corrected for individual brain 
sizes) and medial temporal synaptic loss to properly show the distribution of individual values for both neuro-
imaging data (Fig. 4). The correlation is significant (R = 0.70 and p = 0.010).
Discussion
This exploratory study showed a trend for synaptic loss measured in vivo with SV2A-PET in the anterior para-
hippocampal gyrus of our sample of bvFTD patients, while atrophy was predominant in the ventromedial pre-
frontal cortex. The data in the AD sample were previously reported in a larger  population21. Since comparison 
with bvFTD patients did not provide any significant differences, the results in AD will not be further discussed.
The anterior parahippocampal region corresponds to the rostral perirhinal cortex, that shows high prob-
abilities of connection with the temporal pole, the orbital frontal regions and the frontal pole in the  literature22 
and in our connectivity analysis of fMRI in an independent sample of healthy elderly volunteers. The uncinate 
fasciculus is the connecting tract between those  regions23 and its involvement in bvFTD would be related to 
Figure 3.  Graphic representation of the correlation between  [18F]UCBH distribution volumes (Vt) in caudate 
nucleus and anosognosia for clinical symptoms in bvFTD.
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loss of synaptic projections to the medial temporal  lobe3. The right parahippocampal region (BA36), close to 
the amygdala, is part of the «social brain», involved in perception of socially salient  stimuli24 and of the limbic 
 network25. A relationship between atrophy in the perceptual social network and lack of attention to social cues 
was previously reported in  bvFTD24.
Principal component analysis of FDG-PET previously showed that both frontal and temporal involvement 
are important in  bvFTD26. The importance of temporal involvement in bvFTD was recently re-emphasized with 
TDP-43  studies27. TDP-43 pathology in bvFTD would be initiated in the orbitofrontal cortex and amygdala, pro-
gressing then to frontal and temporal cortices before affecting the motor system, visual cortex and  cerebellum28. 
Patients with bvFTD are associated with TDP-43 type A, involving the frontal, temporal and parietal lobes 
and type B, involving the  hippocampus29. The temporal lobes are shown to be critically affected in C9orf72 
patients linked to TDP-43 pathology types A and  B30, while medial temporal structures are less involved in GRN 
 mutations28. Screening for C9orf72 abnormality was accepted by three patients in our sample but it was negative. 
Temporal involvement was also demonstrated in bvFTD with tau  pathology31,32.
Atrophy was observed in the anteromedial prefrontal cortex. This is consistent with previous studies using 
MRI and FDG-PET18. Considering most (but not all) data reported from post-mortem brain tissue, the absence 
of significant frontal synaptic loss measured in vivo in bvFTD patients is surprising. Tentative explanations may 
be that FDG-PET and SV2A-PET do not measure the same biological phenomenon and that dementia stages 
are different in our living participants and in post-mortem studies. The frontal distribution of  [18F]UCB-H was 
quite variable in our sample of participants (Fig. 5). At a macroscopic level, elevated connectivity was previously 
reported in a dorsal portion of the medial prefrontal cortex and in the frontal pole using resting fMRI in bvFTD 
 patients33,34. At a microscopic level, SV2A-PET is considered as a proxy of synaptic density measurement, but 
it precisely targets one protein of synaptic vesicles. Interestingly, the number of vesicles per synapse was shown 
to be increased in postmortem brain sections from bvFTD patients with PGRN haploinsufficiency, relative to 
 controls35. Why this would occur in frontal cortex and not in the anterior parahippocampal region is unclear. In 
a complementary analysis, we looked for a negative relationship between disease duration and the distribution 
volume of  [18F]UCB-H, and there was no significant correlation that would have provided argument for an early 
increase of synaptic vesicles in the frontal lobe of our patients. Moreover, we did not observe PGRN mutation 
in our three patients who accepted genetic analyses, while loss of synaptic expression measured in the frontal 
cortex of postmortem brains of FTLD patients with SNAP-25 immunochemistry was reported to be influenced 
by different genetic  factors11.
Our correlation analysis suggests that brain atrophy on MRI and synaptic loss on PET-SV2A reflect differ-
ent but correlated pathological processes. Synaptic loss has been studied independently from neuronal loss in 
 FTLD36. Staging of brain pathology was based on  atrophy37 and on pathological protein deposits (mainly TDP43 
or tau)28,38. Atrophy staging was related to neuron loss and gliosis, and not to  synaptopathy39. Accordingly, infor-
mation is currently lacking on the sequence of pathological involvement of neurons such as Von Economo ones, 
particularly affected in  bvFTD40, and their synaptic projections.
Our second result was a significant correlation between greater anosognosia for the clinical symptoms in 
bvFTD patients and lower synaptic density in the caudate nucleus and the frontal pole. It is well recognized that 
beyond behavioral symptoms, patients with bvFTD often exhibit early and severe overestimation of cognitive 
abilities. In previous studies, anosognosia for cognitive impairment was correlated to atrophy in the subgenual 
cingulate  cortex41. The correlation between anosognosia for behavioral symptoms in bvFTD and grey matter 
atrophy did not show any region surviving correction for multiple  comparisons42, while negative correlation 
was observed with glucose uptake in the superior part of the temporal  pole43. In studies where different patient 
groups were combined (including patients with bvFTD), impaired self-awareness was already correlated to 
medial prefrontal cortex  atrophy44.
Figure 5.  Variable frontal  [18F]UCBH distribution (Vt) in bvFTD patients.
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Functional connectivity between the head of the caudate nucleus and the medial prefrontal cortex was previ-
ously  reported45, and recent connectomic analysis of the caudate nucleus demonstrated widespread connections 
with frontal associative cortical regions, comprising areas involved in self-awareness46. Our results are adding the 
head of the caudate nucleus in a network subserving self-awareness, where the caudate nucleus and the pregenual 
ventromedial prefrontal cortex would participate in self reference  processing47, associating a value for the self 
to cognitive or behavioral  information48. Disconnection in such a network was previously reported in  bvFTD33, 
glucose metabolism was already shown to be decreased in caudate and medial frontal regions in  bvFTD49, and 
our correlation analysis demonstrates this network’s involvement in impaired awareness of the patients.
There are several limitations to the study. The sample of bvFTD patients is limited and it comprises partici-
pants with a clinical diagnosis at a very mild to moderate stage, without genetic or pathological confirmation. 
Since plasma neuronal-derived exosomes levels of synaptotagmin and synaptophysin were shown to be decreased 
before dementia is diagnosed in patients with  bvFTD50, participants at very early stages could be studied in the 
next future. We discussed trends for significance in our bvFTD sample, and we compared the results to data 
previously obtained in AD participants, but we did not observe significant between group differences. The PET 
methodology using carotid artery activity as an input function for kinetic modelling was previously  described21,51. 
It certainly deserves further validation and currently it can only provide values of total distribution volume and 
not values of specific binding potential. A recent article on  [11C]UCB-J PET acquisitions in AD showed that 
cerebellum could be used for calculating distribution volume  ratio52. However, cerebellar changes have been 
reported in  bvFTD53. Finally we used a validated measure of anosognosia that is certainly applicable to bvFTD but 
it does not allow to disentangle cognitive from emotional processes that are subserved by different brain regions.
In conclusion, loss of synaptic projections in our sample of bvFTD patients tended to be predominant in the 
right anterior parahippocampal gyrus, probably related to previously reported lesions of the uncinate fasciculus. 
The right anterior parahippocampal gyrus is part of the limbic network and the perceptive social brain, that 
are target functional networks in the disease. A validated measure of anosognosia, a characteristic but variable 
symptom in bvFTD, was related to synaptic density in two interconnected regions, caudate nucleus and antero-
medial prefrontal cortex. The regions are involved in self-referential processes, that are important in developing 
awareness of clinical impairment. Further studies should localize decrease of synaptic projections in prodromal 
bvFTD and use other techniques, such as MRI with neurite orientation dispersion and density imaging (NODDI) 
to further explore the precise distribution of the synaptopathy.
Material and methods
Participants. Three groups of 12 older participants matched for age, sex and education were included in the 
study (Table 1). The first group comprised 12 participants (four women and eight men) with probable  bvFTD18, 
followed in memory clinic. The age range was wide, from 63 to 83 years old. Disease duration was 5.2 ± 3.4 years. 
Apathy was observed in 11 participants, stereotyped behavior and anosognosia in eight, loss of empathy and 
dietary changes in five and disinhibition in three. Clinical Dementia Rating was very mild to  moderate54. None 
had visuospatial deficits, but most complained of memory (n = 11) and executive (n = 8) difficulties. Familial his-
tory of neurodegenerative disorder was reported in seven participants. Visual examination of clinical  [18F]FDG-
PET showed frontal and/or temporal hypometabolism. Delay between  [18F]FDG-PET and  [18F]UCB-H-PET 
was highly variable, with a mean of 22.6 ± 23.5 (range 1–72) months. Accordingly,  [18F]FDG-PET acquired on 
different clinical machines could not be compared to SV2A-PET data, and they were not analyzed as experimen-
tal data. One participant was amyloid-PET negative. Patients were offered genetic testing (tau, GRN, C9orf72), 
but only three accepted.
The second group comprised 12 amyloid-positive patients (five women and seven men) with very mild to 
mild probable Alzheimer’s disease (AD). The diagnosis was based on current NIA-AA  criteria55. Disease dura-
tion was 6.2 ± 3.9 years. As part of the initial diagnostic process,  [18F]FDG-PET was used as a biomarker of 
neurodegeneration in seven patients. Amyloid-β positivity was demonstrated in all patients by qualitative visual 
inspection of  [18F]Flutemetamol-PET.
The third group was composed of 12 cognitively healthy older participants (CTRL, five women and seven 
men) with Mini Mental State Examination (MMSE) score greater than 27/3056. In this control group, amyloid-
negativity was confirmed in four participants using  [18F]Flutemetamol-PET, while there was no biomarker-related 
information for the others. The AD and the control groups were selected from previously published  populations21. 
Written informed consent was obtained from all participants. The study was conducted in accordance with the 
declaration of Helsinki. The study (2014/21) was approved by the Ethics Committee of our University (Comité 
d’Ethique Hospitalo-Facultaire Universitaire de Liège-707).
Neuropsychological assessment. Global cognition was assessed with the MMSE. As diagnosis was done 
at the Memory Clinic, we focused our investigation on few tests and questionnaires guided by theoretical interest 
in the functions of the frontal and temporal brain areas. All participants performed a neuropsychological test 
known to be sensitive to early visual recognition memory deficits related to medial temporal lobe dysfunction, 
 DMS4857. Phonological verbal fluency was measured with letter P during 2 min. Everyday life cognitive func-
tioning and self-awareness were assessed by means of informant-based reports and participants’ reports with 
the Anosognosia Questionnaire for Dementia (AQ-D) that probes cognitive and behavioral  changes58, and the 
Memory Awareness Rating scale-Memory Functioning Scale (MARS-FS) that addresses specifically memory 
 impairment59.
Cerebral image acquisition. Dynamic PET acquisitions were performed using a Siemens/CTI (Knoxville, 
TN) ECAT EXACT HR + PET scanner. 155.93 ± 9.23  MBq of  [18F]UCB-H60 were injected as an intravenous 
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bolus (injected mass, 0.25 ± 0.22 μg). A thermoplastic mask was used to restrain motion during the acquisition. 
The timeframe of the dynamic PET was 6 × 10, 8 × 30, 5 × 120, and 17 × 300 s (total = 100 min). All PET images 
were reconstructed using a filtered backprojection algorithm (Hann filter, 4.9 mm FWHM) and corrected for 
attenuation using a 10  min transmission scan with Germanium-68 sources, dead time, random events, and 
scatter using standard software (ECAT 7.1, Siemens/CTI, Knoxville, TN). With these acquisition and recon-
struction settings, the transaxial image resolution is 6.5 mm in the center of the axial field of view (FOV) and 
the voxel size 2.57 × 2.57 × 2.43  mm3. Blood samples were collected via a catheter inserted in an arm vein in ten 
subjects (two bvFTD, five AD, three CTRL) 3, 5, 15, 45, 60, and 90 min post injection in order to determine 
the plasmatic parent fraction with high performance liquid chromatography. A mean unchanged plasma frac-
tion was calculated for each group and used for  modelling51. Time by group interaction of plasma fraction was 
not significant. In addition, participants underwent a whole-brain quantitative MRI protocol on a 3 T Siemens 
(Erlangen, Germany) Prisma scanner. Multiparameter mapping was based on multi-echo 3D fast low angle shot 
at 1 mm isotropic  resolution61. This included three datasets with T1, proton density (PD), and magnetization 
transfer (MT)–weighted contrasts imposed by the choice of the flip angle (FA = 6° for PD & MT, 21° for T1) and 
the application of an additional off-resonance Gaussian-shaped RF pulse for the MT-weighted acquisition.
Image processing. MRI multiparameter maps were processed with the Voxel-Based Quantification (VBQ) 
 toolbox61 and SPM12 (Wellcome Trust Centre for Neuroimaging, London, UK) to obtain notably a quantitative 
MT map as well as segmented images (grey matter, white matter, CSF, “other”), normalized to the standard MNI 
space using unified  segmentation62. Modulated normalized grey matter images, resized to 2 mm isotropic voxel 
size to approximate to PET images, were smoothed with an isotropic Gaussian kernel of 8 mm of full-width at 
half maximum and analyzed with voxel-based morphometry to identify atrophied regions in the patient groups. 
The modulated normalized grey matter images across the study sample were used to create a grey matter mask 
for the statistical analyses. The PET dynamic images were coregistered to the participant’s structural MT image 
(taking the sum of frames between 2 and 30 min as source image). Then, because of the low resolution of the 
PET scan and because of our main interest in small structures like the hippocampus, the images were corrected 
for partial volume effect (PVE) using the “iterative Yang” voxel-wise method implemented in the PETPVC 
 toolbox63, with grey matter, white matter, CSF and “other” as ROI masks.
The ubiquitous distribution of  [18F]UCB-H in the brain did not allow the identification of a “reference region” 
(with all its necessary characteristics) for a simplified modelling of the radiotracer distribution. Moreover, the 
need of an arterial input function (AIF) is a heavy discomfort for the patient. An alternative method using image-
derived input function was shown to be comparable to that using the AIF for  [18F]UCB-H PET imaging, even if 
the coefficient of variation for measurements was slightly  increased51. So, the input function was derived from 
dynamic PET images. Briefly, the method extracts time series of radiotracer activity in the carotid  arteries64. The 
identification of voxels belonging to the carotids is based on the computation of the Pearson product-moment 
correlation coefficient between a “seeding region” and voxels in a mask containing the carotid. As, radioactivity 
is mainly localized in the vessels during the first 2 min, inducing a large spill-out effect, the signal was corrected 
for this spill-out effect using the geometric transfer matrix  approach65. For each group, the extracted signal was 
then corrected using the corresponding mean unchanged plasma fraction to obtain the input function used for 
modelling. Kinetic modelling using PVE-corrected dynamic PET data and image-derived input function was 
done with PMOD (Version 3.7, PMOD Technologies, Zurich, Switzerland). Logan graphical analysis was used 
to calculate the distribution volume (Vt) map of  [18F]UCB-H in the brain. The t* for Logan analysis was 25 min. 
Finally, the Vt map was normalized into the MNI space using transformation parameters obtained during struc-
tural MRI spatial normalization (2 mm isotropic voxel size).
Statistical analyses. For SPM12 statistical analyses, the normalized PVE-corrected Vt maps were smoothed 
with an isotropic Gaussian kernel of 8 mm of full-width at half maximum. These Vt maps for the three groups 
were entered in a factorial design matrix where two-sample t tests contrasted images 2 × 2. Parameters were 
estimated according to the general linear model at each voxel, using a grey matter mask. Patient-related regional 
synaptic loss was tested by a linear contrast (patients–controls) with a statistical threshold of p < 0.05 with a 
family-wise (FWE) correction for multiple comparisons at the voxel level (no minimal cluster size). Moreover, 
SPM12 multiple regression models allowed to test for correlation between regional  [18F]UCB-H distribution 
volume and each cognitive measure (MMSE, DMS48 proportion of correct responses, verbal fluency score, dis-
crepancy scores between patients’ and informants’ assessments regarding cognitive and behavioral functioning, 
indicative of anosognosia) with a statistical threshold of p < 0.05 FWE-corrected at the voxel level (no minimal 
cluster size). VBM was performed on MT images using SPM12 to compare gray matter images between groups.
Data availability
The data are available upon reasonable request.
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